

# Sabine Vogler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9504819/publications.pdf>

Version: 2024-02-01

65  
papers

1,822  
citations

304743

22  
h-index

276875

41  
g-index

67  
all docs

67  
docs citations

67  
times ranked

1731  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. <i>PLoS Medicine</i> , 2016, 13, e1002032.	8.4	198
2	Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. <i>Lancet Oncology</i> , The, 2016, 17, 39-47.	10.7	137
3	How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 307-321.	2.1	111
4	Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future. <i>Frontiers in Pharmacology</i> , 2017, 8, 171.	3.5	107
5	Pharmaceutical policies in European countries in response to the global financial crisis. <i>Southern Med Review</i> , 2011, 4, 69-79.	0.8	101
6	Differences in external price referencing in Europe – A descriptive overview. <i>Health Policy</i> , 2012, 104, 50-60.	3.0	97
7	The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries – An overview. <i>GaBI Journal</i> , 2012, 1, 93-100.	0.3	77
8	Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 73-78.	1.9	74
9	Payers'™ experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia. <i>Health Policy</i> , 2017, 121, 354-362.	3.0	67
10	Discounts and rebates granted to public payers for medicines in European countries. <i>Southern Med Review</i> , 2012, 5, 38-46.	0.8	49
11	Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States. <i>Croatian Medical Journal</i> , 2011, 52, 183-197.	0.7	48
12	Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure. <i>Frontiers in Pharmacology</i> , 2021, 12, 625296.	3.5	41
13	Analysis of Medicine Prices in New Zealand and 16 European Countries. <i>Value in Health</i> , 2015, 18, 484-492.	0.3	40
14	Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries. <i>Bulletin of the World Health Organization</i> , 2014, 92, 630-640D.	3.3	39
15	Does deregulation in community pharmacy impact accessibility of medicines, quality of pharmacy services and costs? Evidence from nine European countries. <i>Health Policy</i> , 2014, 117, 311-327.	3.0	38
16	The Pharmaceutical Pricing and Reimbursement Information (PPRI) initiative – Experiences from engaging with pharmaceutical policy makers. <i>Health Policy and Technology</i> , 2014, 3, 139-148.	2.5	34
17	Can Price Transparency Contribute to More Affordable Patient Access to Medicines?. <i>PharmacoEconomics - Open</i> , 2017, 1, 145-147.	1.8	34
18	Medicines discarded in household garbage: analysis of a pharmaceutical waste sample in Vienna. <i>Journal of Pharmaceutical Policy and Practice</i> , 2014, 7, 6.	2.4	33

#	ARTICLE	IF	CITATIONS
19	Impact of external price referencing on medicine prices - a price comparison among 14 European countries. <i>Southern Med Review</i> , 2012, 5, 34-41.	0.8	30
20	Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries. <i>Health Policy</i> , 2013, 112, 209-216.	3.0	29
21	Policy interventions related to medicines: Survey of measures taken in European countries during 2010-2015. <i>Health Policy</i> , 2016, 120, 1363-1377.	3.0	28
22	Impact of pharmaceutical policy interventions on utilization of antipsychotic medicines in Finland and Portugal in times of economic recession: interrupted time series analyses. <i>International Journal for Equity in Health</i> , 2014, 13, 53.	3.5	25
23	Inequalities in medicine use in Central Eastern Europe: an empirical investigation of socioeconomic determinants in eight countries. <i>International Journal for Equity in Health</i> , 2015, 14, 124.	3.5	22
24	Price comparison of high-cost originator medicines in European countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 221-230.	1.4	22
25	How to address medicines shortages: Findings from a cross-sectional study of 24 countries. <i>Health Policy</i> , 2020, 124, 1287-1296.	3.0	22
26	The impact of managed entry agreements on pharmaceutical prices. <i>Health Economics (United Kingdom)</i> , 2019, 39, 1071-1087.	1.7	21
27	Pharmaceutical Pricing and Reimbursement Information (PPRI) - New PPRI analysis including Spain. <i>Pharmaceuticals Policy and Law</i> , 2009, 11, 213-234.	0.1	20
28	Tendering for off-patent outpatient medicines: lessons learned from experiences in Belgium, Denmark and the Netherlands. <i>Journal of Pharmaceutical Health Services Research</i> , 2017, 8, 147-158.	0.6	20
29	Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing. <i>PharmacoEconomics - Open</i> , 2019, 3, 303-309.	1.8	20
30	The role of discounts and loss leaders in medicine procurement in Austrian hospitals - a primary survey of official and actual medicine prices. <i>Cost Effectiveness and Resource Allocation</i> , 2013, 11, 15.	1.5	19
31	How large are the differences between originator and generic prices? Analysis of five molecules in 16 European countries. <i>Farmeconomia E Percorsi Terapeutici</i> , 2012, 13, 29-41.	0.1	17
32	Pharmaceutical policies in a crisis? Challenges and solutions identified at the PPRI Conference. <i>Journal of Pharmaceutical Policy and Practice</i> , 2016, 9, 9.	2.4	16
33	Discounts and Rebates Granted for Medicines for Hospital Use in Five European Countries. <i>The Open Pharmacoeconomics &amp; Health Economics Journal</i> , 2013, 5, 1-10.	0.6	16
34	Review of studies reporting actual prices for medicines. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 159-179.	1.4	14
35	Fair prices for medicines? Exploring competent authorities' and public payers' preferences on pharmaceutical policies. <i>Empirica</i> , 2019, 46, 443-469.	1.8	12
36	Understanding the components of pharmaceutical expenditure - overview of pharmaceutical policies influencing expenditure across European countries. <i>GaBI Journal</i> , 2013, 2, 178-187.	0.3	12

#	ARTICLE	IF	CITATIONS
37	Medicines with one seller and many buyers: strategies to increase the power of the payer. <i>BMJ</i> , The, 2020, 369, m1705.	6.0	11
38	European collaborations on medicine and vaccine procurement. <i>Bulletin of the World Health Organization</i> , 2021, 99, 715-721.	3.3	10
39	Balancing access to medicines and sustainability in Europe: An analysis from the network of competent authorities on pricing and reimbursement (CAPR). <i>Pharmacological Research</i> , 2016, 111, 247-250.	7.1	9
40	Financial Burden of Prescribed Medicines Included in Outpatient Benefits Package Schemes: Comparative Analysis of Co-Payments for Reimbursable Medicines in European Countries. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 803-816.	2.1	9
41	Can we achieve affordable cancer medicine prices? Developing a pathway for change. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 321-325.	1.4	9
42	Stakeholder preferences about policy objectives and measures of pharmaceutical pricing and reimbursement. <i>Health Policy and Technology</i> , 2016, 5, 213-225.	2.5	8
43	Public spending on orphan medicines: a review of the literature. <i>Journal of Pharmaceutical Policy and Practice</i> , 2020, 13, 66.	2.4	8
44	Centralised Pharmaceutical Procurement: Learnings from Six European Countries. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 637-650.	2.1	7
45	The Pharmaceutical Pricing and Reimbursement Information (PPRI) network – a decade of exchange of information and policy research?. <i>Journal of Pharmaceutical Policy and Practice</i> , 2015, 8, .	2.4	6
46	Affordable and equitable access to subsidised outpatient medicines? Analysis of co-payments under the Additional Drug Package in Kyrgyzstan. <i>International Journal for Equity in Health</i> , 2019, 18, 89.	3.5	5
47	Assessing Data Sources for Medicine Price Studies. <i>International Journal of Technology Assessment in Health Care</i> , 2019, 35, 106-115.	0.5	5
48	Addressing the medicines access challenge through balance, evidence, collaboration and transparency: key take-away lessons of the 4th PPRI Conference. <i>Journal of Pharmaceutical Policy and Practice</i> , 2021, 14, 18.	2.4	5
49	Biosimilars in Deutschland und im europÄischen Vergleich – Entwicklungen und Potenziale. , 2019, , 321-353.		5
50	Marktzugang, Erstattung und Preissetzung neuer patentgeschÄtzter Arzneimittel in der EuropÄischen Union. , 2018, , 239-260.		5
51	Policy options to deal with high-cost medicines – survey with European policy-makers. <i>Journal of Pharmaceutical Policy and Practice</i> , 2015, 8, .	2.4	4
52	Impact of changes in the methodology of external price referencing on medicine prices: discrete-event simulation. <i>Cost Effectiveness and Resource Allocation</i> , 2020, 18, 51.	1.5	4
53	Biosimilars in Deutschland und im europÄischen Vergleich – Marktsteuerungsmechanismen und Einsparpotenziale. , 2020, , 201-225.		4
54	Practice of External Price Referencing. , 2019, , 345-368.		3

#	ARTICLE	IF	CITATIONS
55	Biologika und Biosimilars in Deutschland und im europ�ischen Vergleich â€“ Marktsteuerungsmechanismen und Preisvergleich. , 2021, , 75-107.		3
56	Purchasing medicines for the public sector: Evaluation of the performance of centralised procurement in Portugal. International Journal of Health Planning and Management, 2022, 37, 2007-2031.	1.7	3
57	Access to High-Cost Medicines in Europe. , 2018, , 143-164.		2
58	Medicines Pricing: Limitations of Existing Policies and New Models. , 2020, , 99-137.		2
59	Pharmaceutical regulation and policies in Austria. Revista Brasileira De Farm�cia Hospitalar E Servi�os De Sa�de, 2022, 13, 639.	0.1	2
60	Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?. Global & Regional Health Technology Assessment, 0, 8, 114-119.	0.1	1
61	Preisregulierungen im internationalen Vergleich. , 2021, , 125-138.		1
62	"Ready for the future?" - Status of national and cross-country horizon scanning systems for medicines in European countries.. GMS German Medical Science, 2022, 20, Doc05.	2.7	1
63	External Price Referencing Policy Brief. , 2019, , 433-439.		0
64	Price Studies for Specific Medicines. , 2019, , 113-164.		0
65	Assessment of External Price Referencing and Alternative Policies. , 2019, , 369-419.		0